Long-term Follow-up of 241 Patients With Monoclonal Gammopathy of Undetermined Significance: The Original Mayo Clinic Series 25 Years Later

2004 ◽  
Vol 79 (7) ◽  
pp. 859-866 ◽  
Author(s):  
Robert A. Kyle ◽  
Terry M. Therneau ◽  
S. Vincent Rajkumar ◽  
Dirk R. Larson ◽  
Matthew F. Plevak ◽  
...  
Keyword(s):  
Mayo Clinic ◽  
Monoclonal Gammopathy ◽  
Long Term Follow Up ◽  
Undetermined Significance

scholarly journals Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance

2018 ◽  
Vol 378 (3) ◽  
pp. 241-249 ◽  
Author(s):  
Robert A. Kyle ◽  
Dirk R. Larson ◽  
Terry M. Therneau ◽  
Angela Dispenzieri ◽  
Shaji Kumar ◽  
...  
Keyword(s):  
Monoclonal Gammopathy ◽  
Long Term Follow Up ◽  
Undetermined Significance

Long-Term Follow-Up of Patients with Monoclonal Gammopathy of Undetermined Significance after Kidney Transplantation

2012 ◽  
Vol 35 (4) ◽  
pp. 365-371 ◽  
Author(s):  
Harris V.K. Naina ◽  
Samar Harris ◽  
Angela Dispenzieri ◽  
Fernando G. Cosio ◽  
Thomas M. Habermann ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Monoclonal Gammopathy ◽  
Long Term Follow Up ◽  
Undetermined Significance

Long-term follow-up of IgM monoclonal gammopathy of undetermined significance

2003 ◽  
Vol 30 (2) ◽  
pp. 169-171 ◽  
Author(s):  
R.A. Kyle ◽  
T.M. Therneau ◽  
S.V. Rajkumar ◽  
J.R. Offord ◽  
D.R Larson ◽  
...  
Keyword(s):  
Monoclonal Gammopathy ◽  
Long Term Follow Up ◽  
Undetermined Significance

Long-Term Follow-Up of Monoclonal Gammopathy of Undetermined Significance in Transplant Patients

1994 ◽  
Vol 14 (3) ◽  
pp. 187-191 ◽  
Author(s):  
Lionel Rostaing ◽  
Anne Modesto ◽  
Michel Abbal ◽  
Dominique Durand
Keyword(s):  
Monoclonal Gammopathy ◽  
Transplant Patients ◽  
Long Term Follow Up ◽  
Undetermined Significance

scholarly journals A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ka-Won Kang ◽  
Ji Eun Song ◽  
Byung-Hyun Lee ◽  
Min Ji Jeon ◽  
Eun Sang Yu ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Disease Progression ◽  
Monoclonal Gammopathy ◽  
Chronic Kidney Failure ◽  
Real World Data ◽  
Nationwide Study ◽  
Long Term Follow Up ◽  
Undetermined Significance

AbstractIn clinical practice, most patients with monoclonal gammopathy of undetermined significance (MGUS) undergo long-term follow-up without disease progression. There is insufficient real-world data about how closely and whether anything other than disease progression should be monitored. Herein, we performed a nationwide study of 470 patients with MGUS with a 10-year follow-up to determine the patterns of disease progression and other comorbidities. During the follow-up period, 158 of 470 patients with MGUS (33.62%) progressed to symptomatic monoclonal gammopathies. Most of these were multiple myeloma (134/470 patients, 28.51%), and those diagnosed within 2 years after diagnosis of MGUS was high. Approximately 30–50% of patients with MGUS had hypertension, diabetes, hyperlipidemia, and osteoarthritis at the time of diagnosis, and these comorbidities were newly developed during the follow-up period in approximately 50% of the remaining patients with MGUS. Approximately 20–40% of patients with MGUS have acute or chronic kidney failure, thyroid disorders, disc disorders, peripheral neuropathy, myocardial infarction, stroke, and heart failure during the follow-up period. Altogether, when MGUS is diagnosed, close follow-up of the possibility of progression to multiple myeloma is required, especially within 2 years after diagnosis; simultaneously, various comorbidities should be considered and monitored during the follow-up of patients with MGUS. Continuous research is needed to establish appropriate follow-up guidelines.

scholarly journals How I manage monoclonal gammopathy of undetermined significance

Blood ◽  
2018 ◽  
Vol 131 (2) ◽  
pp. 163-173 ◽  
Author(s):  
Ronald S. Go ◽  
S. Vincent Rajkumar
Keyword(s):  
Monoclonal Gammopathy ◽  
Limited Evidence ◽  
Immunoglobulin Light Chain ◽  
High Prevalence ◽  
Long Term Follow Up ◽  
Immunoglobulin Light Chain Amyloidosis ◽  
Undetermined Significance ◽  
Academic Debate

Abstract Monoclonal gammopathy of undetermined significance (MGUS) is, in many ways, a unique hematologic entity. Unlike most hematologic conditions in which the diagnosis is intentional and credited to hematologists, the discovery of MGUS is most often incidental and made by nonhematologists. MGUS is considered an obligate precursor to several lymphoplasmacytic malignancies, including immunoglobulin light-chain amyloidosis, multiple myeloma, and Waldenström macroglobulinemia. Therefore, long-term follow-up is generally recommended. Despite its high prevalence, there is surprisingly limited evidence to inform best clinical practice both at the time of diagnosis and during follow-up. We present 7 vignettes to illustrate common clinical management questions that arise during the course of MGUS. Where evidence is present, we provide a concise summary of the literature and clear recommendations on management. Where evidence is lacking, we describe how we practice and provide a rationale for our approach. We also discuss the potential harms associated with MGUS diagnosis, a topic that is rarely, if ever, broached between patients and providers, or even considered in academic debate.

Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic

2020 ◽  
Vol 95 (5) ◽  
pp. 944-954
Author(s):  
Aishwarya Ravindran ◽  
Kandace A. Lackore ◽  
Amy E. Glasgow ◽  
Matthew T. Drake ◽  
Miriam A. Hobbs ◽  
...  
Keyword(s):  
Mayo Clinic ◽  
Monoclonal Gammopathy ◽  
Undetermined Significance

scholarly journals Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications

Blood ◽  
2010 ◽  
Vol 116 (12) ◽  
pp. 2019-2025 ◽  
Author(s):  
Giada Bianchi ◽  
Robert A. Kyle ◽  
Colin L. Colby ◽  
Dirk R. Larson ◽  
Shaji Kumar ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Laboratory Testing ◽  
Monoclonal Gammopathy ◽  
Incidental Finding ◽  
Optimal Frequency ◽  
Future Studies ◽  
Risk Of Progression ◽  
Undetermined Significance

Abstract Monoclonal gammopathy of undetermined significance (MGUS) is associated with a long-term risk of progression to multiple myeloma (MM) or related malignancy. To prevent serious myeloma-related complications, lifelong annual follow-up has been recommended, but its value is unknown. We reviewed all patients from southeastern Minnesota seen at Mayo Clinic between 1973 and 2004 with MGUS who subsequently progressed to MM. Of 116 patients, 69% had optimal follow-up of MGUS. Among these, abnormalities on serial follow-up laboratory testing led to the diagnosis of MM in 16%, whereas MM was diagnosed only after serious MM-related complications in 45%. In the remaining, workup of less serious symptoms (25%), incidental finding during workup of unrelated medical conditions (11%), and unknown (3%) were the mechanisms leading to MM diagnosis. High-risk MGUS patients (≥ 1.5 g/dL and/or non-IgG MGUS) were more likely to be optimally followed (81% vs 64%), and be diagnosed with MM secondary to serial follow-up testing (21% vs 7%). This retrospective study suggests that routine annual follow-up of MGUS may not be required in low-risk MGUS. Future studies are needed to replicate and expand our findings and to determine the optimal frequency of monitoring in higher-risk MGUS patients.

Sign in / Sign up

Export Citation Format

Share Document